Compare CHE & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHE | PCVX |
|---|---|---|
| Founded | 1970 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.0B |
| IPO Year | 1994 | 2020 |
| Metric | CHE | PCVX |
|---|---|---|
| Price | $512.36 | $60.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $571.60 | $117.30 |
| AVG Volume (30 Days) | 120.6K | ★ 3.4M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 9.97 | N/A |
| Revenue | ★ $2,529,978,000.00 | N/A |
| Revenue This Year | $7.56 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | $52.18 | ★ N/A |
| Revenue Growth | ★ 4.06 | N/A |
| 52 Week Low | $365.21 | $39.87 |
| 52 Week High | $557.00 | $90.75 |
| Indicator | CHE | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 45.93 |
| Support Level | $495.72 | $52.91 |
| Resistance Level | $518.25 | $62.00 |
| Average True Range (ATR) | 10.24 | 4.10 |
| MACD | 1.70 | -0.68 |
| Stochastic Oscillator | 68.18 | 2.27 |
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.